We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

By LabMedica International staff writers
Posted on 30 Apr 2025

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. More...

However, around 1 in 5 individuals with myeloma have a high-risk form of the disease, which is marked by an earlier relapse following initial treatment. This leads to a shorter survival period, typically just 2-3 years. A key challenge for clinicians is predicting when relapse will occur so that patients can be treated with effective alternative therapies before the disease advances. Now, a research team is evaluating a new mass spectrometry-based monitoring technique to determine its ability to predict and identify early relapses of the disease.

The introduction of more effective therapies over the past two decades has significantly improved survival rates for myeloma patients. The most recent generation of myeloma drugs includes therapeutic monoclonal antibodies (t-mAb), which have shown remarkable efficacy. However, these drugs can interfere with traditional electrophoretic methods used to measure the patient’s monoclonal immunoglobulin (M-Ig), making patient monitoring more challenging. Therefore, alternative laboratory methods that address the limitations of these conventional approaches are needed. Oxford University Hospitals (Oxford, UK), in collaboration with other institutions, is leading the investigation into a new monitoring method known as quantitative immunoprecipitation-mass spectrometry (QIP-MS). The research team will assess whether QIP-MS can predict and detect relapse earlier than current methods in patients with high-risk myeloma participating in the Myeloma XV RADAR trial. This trial involves analyzing bone marrow samples to determine the most effective treatments for myeloma and aims to measure small amounts of myeloma cells, referred to as minimal residual disease (MRD), that may persist after initial treatment.

Previous research has shown that QIP-MS is clinically useful as a first-line screening tool for investigating monoclonal gammopathy, offering higher sensitivity and resolution than the standard methods currently in use. Serum or urine protein electrophoresis (SPEP or UPEP) and immunofixation electrophoresis (SIFE or UIFE) are commonly used to detect M-proteins in multiple myeloma patients. However, SPEP and SIFE are not sufficiently sensitive to detect low levels of M-proteins, which may still be clinically significant. QIP-MS, on the other hand, allows for the identification of M-proteins in patients with multiple myeloma who are otherwise in complete remission, and could be ideal for evaluating MRD in peripheral blood. One significant advantage of QIP-MS is that it uses blood samples rather than bone marrow, which, if proven to be more sensitive, would reduce the need for painful procedures during regular monitoring for patients.


New
Gold Member
Latex Test
SLE-Latex Test
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Fixed Speed Tube Rocker
GTR-FS
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.